Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 4/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.50 |
| ▸ | PGR | P06401 | 4/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31472193 | 1.00 | TNKS (0.50) | TNKSTNKS2PGRBACE1SRD5A1 | |
| SCHEMBL24481758 | 0.93 | TNKS (0.51) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL31472145 | 0.93 | TNKS (0.51) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL15004855 | 0.93 | TNKS (0.51) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL4719403 | 0.91 | TNKS (0.50) | TNKSTNKS2PGRBACE1PDE7A | |
| SCHEMBL20954874 | 0.90 | BACE1 (0.51) | TNKSTNKS2PGRBACE1SRD5A1 | |
| SCHEMBL15650376 | 0.88 | TNKS (0.46) | TNKSTNKS2PGRBACE1HDAC4 | |
| SCHEMBL31414295 | 0.81 | TNKS (0.40) | TNKSTNKS2PGRBACE1SRD5A1 | |
| SCHEMBL19235306 | 0.79 | TNKS (0.47) | TNKSTNKS2CYP2C19 | |
| SCHEMBL17556137 | 0.78 | TNKS (0.49) | TNKSTNKS2PGRBACE1PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319204-A1 | PROCESS FOR THE SYNTHESIS OF PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2008-12-25 | — | — | US | claimed |
| US-20080051585-A1 | Process for the preparation of indolin-2-one derivatives useful as PR modulators | WYETH (US) | 2008-02-28 | — | — | US | claimed |
| WO-2008021422-A2 | PROCESS FOR THE PREPARATION OF INDOLIN-2-ONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | claimed |
| US-11793815-B2 | Oxindoles and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4240722-A1 | OXINDOLES AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20220143031-A1 | OXINDOLES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2022099066-A1 | OXINDOLES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMAN-LA ROCHE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-7595338-B2 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080319204-A1 | PROCESS FOR THE SYNTHESIS OF PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080319204-A1 | PROCESS FOR THE SYNTHESIS OF PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080319204-A1 | PROCESS FOR THE SYNTHESIS OF PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080051585-A1 | Process for the preparation of indolin-2-one derivatives useful as PR modulators | WYETH (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051585-A1 | Process for the preparation of indolin-2-one derivatives useful as PR modulators | WYETH (US) | 2008-02-28 | — | — | US | disclosed |
| US-20080051585-A1 | Process for the preparation of indolin-2-one derivatives useful as PR modulators | WYETH (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2008021422-A2 | PROCESS FOR THE PREPARATION OF INDOLIN-2-ONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021422-A2 | PROCESS FOR THE PREPARATION OF INDOLIN-2-ONE DERIVATIVES USEFUL AS PR MODULATORS | WYETH (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | WYETH (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | TNKS 1726/4885TNKS2 2728/4885PGR 1662/4885 |
| US-11793815-B2 | Oxindoles and methods of use thereof | CYP11B2, OXTR, CYP11B1 | TNKS 2879/4885TNKS2 2562/4885PGR 2601/4885 |
| US-20080319204-A1 | PROCESS FOR THE SYNTHESIS OF PROGESTERONE RECEPTOR MODULATORS | OXTR, PGR, NR3C2 | TNKS 3875/4885TNKS2 3162/4885PGR 2/4885 |
| US-20220143031-A1 | OXINDOLES AND METHODS OF USE THEREOF | CYP11B2, OXTR, CYP11B1 | TNKS 2879/4885TNKS2 2562/4885PGR 2601/4885 |
| US-20080051585-A1 | Process for the preparation of indolin-2-one derivatives useful as PR modulators | IDO1, INMT, PIR | TNKS 94/4885TNKS2 159/4885PGR 954/4885 |
| US-20060247441-A1 | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles | TPMT, TH, HTR3C | TNKS 246/4885TNKS2 298/4885PGR 3670/4885 |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | TNKS 1726/4885TNKS2 2728/4885PGR 1662/4885 |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | IDO1, ZC3HAV1, AZI2 | TNKS 1889/4885TNKS2 2838/4885PGR 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.